Free Trial

Legend Biotech (LEGN) Stock Price, News & Analysis

Legend Biotech logo
$45.02
+0.75 (+1.69%)
(As of 10/31/2024 ET)

About Legend Biotech Stock (NASDAQ:LEGN)

Key Stats

Today's Range
$43.74
$45.28
50-Day Range
$42.87
$57.55
52-Week Range
$38.60
$70.13
Volume
1.01 million shs
Average Volume
1.06 million shs
Market Capitalization
$8.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$82.08
Consensus Rating
Buy

Company Overview

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Legend Biotech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

LEGN MarketRank™: 

Legend Biotech scored higher than 40% of companies evaluated by MarketBeat, and ranked 761st out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Legend Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Legend Biotech has only been the subject of 4 research reports in the past 90 days.

  • Read more about Legend Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Legend Biotech are expected to grow in the coming year, from ($1.48) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Legend Biotech is -57.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Legend Biotech is -57.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Legend Biotech has a P/B Ratio of 6.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Legend Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    6.55% of the outstanding shares of Legend Biotech have been sold short.
  • Short Interest Ratio / Days to Cover

    Legend Biotech has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Legend Biotech has recently decreased by 0.99%, indicating that investor sentiment is improving.
  • Dividend Yield

    Legend Biotech does not currently pay a dividend.

  • Dividend Growth

    Legend Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.55% of the outstanding shares of Legend Biotech have been sold short.
  • Short Interest Ratio / Days to Cover

    Legend Biotech has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Legend Biotech has recently decreased by 0.99%, indicating that investor sentiment is improving.
  • News Sentiment

    Legend Biotech has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Legend Biotech this week, compared to 5 articles on an average week.
  • Search Interest

    Only 5 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Legend Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.02% of the stock of Legend Biotech is held by insiders.

  • Percentage Held by Institutions

    70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Legend Biotech's insider trading history.
Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

LEGN Stock News Headlines

Legend Biotech participates in a conference call with JPMorgan
I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
RBC Capital Remains a Buy on Legend Biotech (LEGN)
Legend Biotech’s AGM Highlights Shareholder Confidence
See More Headlines

LEGN Stock Analysis - Frequently Asked Questions

Legend Biotech's stock was trading at $60.17 at the beginning of 2024. Since then, LEGN shares have decreased by 25.2% and is now trading at $45.02.
View the best growth stocks for 2024 here
.

Legend Biotech Co. (NASDAQ:LEGN) announced its earnings results on Friday, August, 9th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.49. The company's revenue for the quarter was up 154.4% compared to the same quarter last year.

Legend Biotech (LEGN) raised $350 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO.

Legend Biotech's top institutional investors include Empire Life Investments Inc. (0.05%), E Fund Management Hong Kong Co. Ltd. (0.03%), Handelsbanken Fonder AB (0.03%) and Diversified Trust Co (0.02%).

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
8/09/2024
Today
10/31/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LEGN
Fax
N/A
Employees
1,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$82.08
High Stock Price Target
$94.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+85.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
14 Analysts

Profitability

Net Income
$-518,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$455.99 million
Book Value
$6.88 per share

Miscellaneous

Free Float
182,269,000
Market Cap
$8.07 billion
Optionable
Optionable
Beta
0.10
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:LEGN) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners